BG105149A - Тиобензимидазолови производни - Google Patents

Тиобензимидазолови производни

Info

Publication number
BG105149A
BG105149A BG105149A BG10514901A BG105149A BG 105149 A BG105149 A BG 105149A BG 105149 A BG105149 A BG 105149A BG 10514901 A BG10514901 A BG 10514901A BG 105149 A BG105149 A BG 105149A
Authority
BG
Bulgaria
Prior art keywords
thiobenzimidazole derivatives
human chymase
thiobenzimidazole
derivatives
preventives
Prior art date
Application number
BG105149A
Other languages
English (en)
Other versions
BG65514B1 (bg
Inventor
Yoshiyuki Matsumoto
Susumu Takeuchi
Naoki Hase
Original Assignee
Teijin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Limited filed Critical Teijin Limited
Publication of BG105149A publication Critical patent/BG105149A/bg
Publication of BG65514B1 publication Critical patent/BG65514B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Съединенията или техните фармацевтично приемливи соли имат формула@@Те инхибират човешка химаза и са клинично приложими профилактични и/или лечебни средства при различни заболявания, в които участва човешката химаза.
BG105149A 1998-07-15 2001-01-15 Тиобензимидазолови производни BG65514B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20025098 1998-07-15

Publications (2)

Publication Number Publication Date
BG105149A true BG105149A (bg) 2001-08-31
BG65514B1 BG65514B1 (bg) 2008-10-31

Family

ID=16421274

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105149A BG65514B1 (bg) 1998-07-15 2001-01-15 Тиобензимидазолови производни

Country Status (22)

Country Link
US (2) US7268145B2 (bg)
EP (1) EP1097926A4 (bg)
JP (1) JP3923255B2 (bg)
KR (1) KR100903531B1 (bg)
CN (1) CN1187337C (bg)
AU (1) AU758789B2 (bg)
BG (1) BG65514B1 (bg)
BR (1) BR9912098A (bg)
CA (1) CA2336909C (bg)
EE (1) EE04904B1 (bg)
HR (1) HRP20010030A2 (bg)
HU (1) HUP0103256A3 (bg)
ID (1) ID26899A (bg)
IL (1) IL140862A (bg)
IS (1) IS5807A (bg)
NO (1) NO318957B1 (bg)
NZ (1) NZ509207A (bg)
PL (1) PL203730B1 (bg)
RU (1) RU2237663C2 (bg)
SK (1) SK212001A3 (bg)
TR (1) TR200100047T2 (bg)
WO (1) WO2000003997A1 (bg)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3923255B2 (ja) 1998-07-15 2007-05-30 帝人株式会社 チオベンズイミダゾール誘導体
US20040010004A1 (en) 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
JP2007119478A (ja) * 1998-07-15 2007-05-17 Teijin Ltd チオベンズイミダゾール誘導体
US20030083315A1 (en) * 2000-01-17 2003-05-01 Naoki Tsuchiya Human chymase inhibitors
EP1249450B1 (en) * 2000-01-17 2007-10-10 Teijin Pharma Limited Benzimidazole derivatives as human chymase inhibitors
WO2001062294A1 (fr) 2000-02-22 2001-08-30 Suntory Limited Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter des dermatites
JP4759500B2 (ja) * 2001-02-22 2011-08-31 帝人株式会社 ベンゾ［ｂ］チオフェン誘導体、およびその製造方法
NZ522150A (en) 2001-02-22 2006-03-31 Teijin Ltd Benzo[b]thiophene derivatives and processes for preparing the same
WO2004007464A1 (ja) * 2002-07-10 2004-01-22 Sumitomo Pharmaceuticals Co., Ltd. イミダゾール誘導体
CL2004001034A1 (es) * 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
WO2005018672A1 (ja) * 2003-08-22 2005-03-03 Teijin Pharma Limited キマーゼ阻害剤を有効成分として含有する薬剤
BRPI0514611A (pt) * 2004-08-26 2008-06-17 Actelion Pharmaceuticals Ltd uso de um composto, compostos, e, medicamento
EP1826207A4 (en) * 2004-11-12 2009-05-20 Teijin Pharma Ltd ACID SALT OF A BENZIMIDAZOLE DERIVATIVE AND CRYSTAL THEREOF
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
JP4339371B2 (ja) * 2007-03-22 2009-10-07 株式会社ソニー・コンピュータエンタテインメント 情報処理装置および情報処理方法
TW200916098A (en) * 2007-06-14 2009-04-16 Teijin Pharma Ltd Agent for lowering uric acid level
WO2009133964A1 (ja) * 2008-04-28 2009-11-05 国立大学法人九州大学 酸化ストレス抑制剤
WO2010036613A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051176A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2888008B1 (en) 2012-08-22 2018-12-26 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydrofuran derivatives
US9382243B2 (en) 2012-08-22 2016-07-05 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydropyran derivatives
EP2906040B1 (en) 2012-08-22 2021-02-17 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
EP2887807B1 (en) 2012-08-22 2019-09-18 Merck Sharp & Dohme Corp. Benzimidazole hexahydrofuro[3,2-b]furan derivatives useful as amp-activated protein kinase activators
WO2014031441A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
BR112015003109A2 (pt) 2012-08-22 2017-08-15 Merck Sharp & Dohme Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2.
KR101435496B1 (ko) * 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5617073B2 (bg) * 1971-10-28 1981-04-20
DE2648411C2 (de) * 1976-10-26 1984-05-17 Mtu Motoren- Und Turbinen-Union Friedrichshafen Gmbh, 7990 Friedrichshafen Mehrzylindrige Dieselbrennkraftmaschine
FR2430950A1 (fr) 1978-07-10 1980-02-08 Delalande Sa Nouveaux derives heterocycliques de la benzimidazole, leur procede de preparation et leur application en therapeutique
US4312308A (en) * 1980-02-21 1982-01-26 Slattery Gordon C Compression relief system for internal combustion engine
JPS62212386A (ja) 1986-03-14 1987-09-18 Suntory Ltd ２−ピリジルメチルベンズイミダゾ−ル誘導体
EP0251536A1 (en) 1986-06-24 1988-01-07 FISONS plc Benzimidazoles, their production, formulation and use as gastric acid secretion inhibitors
US4839365A (en) 1987-05-19 1989-06-13 Shinogi & Co., Ltd. Thienopyridine derivatives useful in treating gastric ulcers
AT389107B (de) 1987-12-03 1989-10-25 Fisons Plc Neue benzimidazole, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
JPH01265089A (ja) 1988-04-15 1989-10-23 Zeria Pharmaceut Co Ltd 新規１−（イミダゾール−４−イル）メチルベンズイミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
US5128339A (en) 1990-11-01 1992-07-07 Sterling Winthrop Inc. Proteolytic enzyme inhibition method
GB8911453D0 (en) 1989-05-18 1989-07-05 Minnesota Mining & Mfg Speed and contrast promoted silver halide rhodium doped emulsions
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
JPH0314566A (ja) 1989-06-09 1991-01-23 Sankyo Co Ltd ベンズイミダゾール誘導体
US5449682A (en) 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
FR2658511B1 (fr) * 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5128359A (en) 1990-02-16 1992-07-07 Laboratoires Upsa Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5374615A (en) 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
CA2061159A1 (en) 1991-02-26 1992-08-27 Michael A. Poss Imidazole and benzimidazole derivatives
US5191086A (en) 1991-03-19 1993-03-02 E.R. Squibb & Sons, Inc. Imidazole and benzimidazole derivatives
US5128327A (en) 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
TW300219B (bg) 1991-09-14 1997-03-11 Hoechst Ag
JPH05112559A (ja) 1991-10-18 1993-05-07 Morishita Roussel Kk ４−アミノ−５−ピリミジンカルボン酸誘導体
EP0577023A3 (en) 1992-07-01 1996-12-18 Hoechst Ag Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
EP0721944B1 (en) 1994-07-29 2001-01-17 Suntory Limited Imidazolidine derivative and use thereof
JPH08208654A (ja) 1994-11-24 1996-08-13 Wakamoto Pharmaceut Co Ltd キマーゼ活性を阻害し、かつ一酸化窒素生成を抑制する新規トリアジン誘導体
DE69634122D1 (de) 1995-04-27 2005-02-03 Mitsubishi Pharma Corp Heterocyclische amidverbindungen und deren medizinische verwendung
EP0849259A4 (en) 1995-07-17 1998-11-11 Fuji Photo Film Co Ltd BENZIMIDAZOLE COMPOUNDS
JP3537231B2 (ja) 1995-07-24 2004-06-14 第一サントリーファーマ株式会社 ヒダントイン誘導体およびその用途
DE69622148T2 (de) 1995-09-28 2002-10-31 Suntory Limited, Osaka Chinazozin derivate und deren verwendung
CA2264020A1 (en) 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
CN1088706C (zh) 1996-10-25 2002-08-07 卫福有限公司 新型杂环酰胺化合物及其医药用途
WO1999026932A1 (en) 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
AU3538899A (en) 1998-04-30 1999-11-23 Nippon Chemiphar Co. Ltd. Condensed imidazole derivative and therapeutic agent for liver disease
JP3923255B2 (ja) 1998-07-15 2007-05-30 帝人株式会社 チオベンズイミダゾール誘導体
EA004746B1 (ru) 1999-06-28 2004-08-26 Янссен Фармацевтика Н.В. Производные бензимидазола и имидазопиридина в качестве ингибиторов репликации респираторно-синцитиального вируса

Also Published As

Publication number Publication date
US20070275995A1 (en) 2007-11-29
HRP20010030A2 (en) 2001-12-31
SK212001A3 (en) 2001-11-06
US7268145B2 (en) 2007-09-11
IL140862A0 (en) 2002-02-10
EP1097926A1 (en) 2001-05-09
WO2000003997A1 (fr) 2000-01-27
NO20010193L (no) 2001-01-12
NZ509207A (en) 2003-01-31
CN1187337C (zh) 2005-02-02
EE200100022A (et) 2002-06-17
JP3923255B2 (ja) 2007-05-30
BG65514B1 (bg) 2008-10-31
CN1316998A (zh) 2001-10-10
PL203730B1 (pl) 2009-11-30
IL140862A (en) 2005-05-17
KR100903531B1 (ko) 2009-06-23
AU758789B2 (en) 2003-03-27
KR20010079527A (ko) 2001-08-22
ID26899A (id) 2001-02-15
EE04904B1 (et) 2007-10-15
NO318957B1 (no) 2005-05-30
BR9912098A (pt) 2001-09-25
TR200100047T2 (tr) 2001-10-22
EP1097926A4 (en) 2004-06-30
US20060040976A1 (en) 2006-02-23
HUP0103256A3 (en) 2002-05-28
HUP0103256A2 (hu) 2002-04-29
PL345540A1 (en) 2001-12-17
AU4651999A (en) 2000-02-07
CA2336909A1 (en) 2000-01-27
RU2237663C2 (ru) 2004-10-10
IS5807A (is) 2001-01-12
CA2336909C (en) 2009-10-20
NO20010193D0 (no) 2001-01-12

Similar Documents

Publication Publication Date Title
BG105149A (bg) Тиобензимидазолови производни
BG103945A (bg) Производни на 4"-заместен-9-деоксо-9а-аза-9а- хомоеритромицин а
EP0795548A4 (en) CHINAZOZINE DERIVATIVES AND THEIR USE
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
BG106586A (bg) Пиразолопиримидини като терапевтични средства
BG106003A (bg) Нови n-цианометиламиди и състави като протеазни инхибитори
YU69902A (sh) Novi derivati piperazina
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BG104631A (bg) Сулфонамидни производни,фармацевтични състави и използването им като пролекарства на аспартилпротеазни инхибитори
WO2003037864A1 (fr) Compose indolique, et utilisation a des fins therapeutiques
MX9700885A (es) Nuevas heteroariloxazolidinonas.
MY134880A (en) Thiazolyl amide derivatives
AU3850600A (en) Dalda analogs and their use
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
ATE322487T1 (de) Hydroxamsäure-derivate
AU6797298A (en) Halo-alkoxycarbonyl prodrugs
BG104447A (bg) Бифениламидинови производни
EP1602645A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVE WITH 2,6-DISUBSTITUTED STYRYL REST
YU30603A (sh) Derivati premošćenog piperazina
IL143985A0 (en) New use of melagatran
MX9700807A (es) Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
EP1191022A4 (en) NEW DIHYDROPYRIDINE DERIVATIVES
WO2005053702A3 (en) Anti-inflammatory agents
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
EP0842663A4 (en) OPHTHALMIC PREPARATIONS